Delius Pharmaceuticals has said that it has registered a 35 percent increase in sales and turnover in FY 23-24. The API division has also registered a remarkable growth of 60 percent, the company said. “This success isn’t just about financial growth; it’s a tale of dedication to producing top-notch pharmaceuticals,” the company said, announcing its performance. It also announced plans to launch an IPO in the next few years.
“The impressive growth is a result of quality products and assertive marketing strategies. Delius Pharmaceuticals is poised for significant market impact. We see a future where Delius not only dominates the Pharma Industry in India but also expands globally,” said Chief Sales Officer Sahil. “We are planning an initial public offering (IPO) within 2-3 years,” Sahil added.
Our mission extends beyond profit, aiming to establish more manufacturing units and provide employment opportunities for nearly 500 individuals.
